Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Endocrinology ; 155(4): 1398-406, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24428527

ABSTRACT

The decline in testosterone levels in men during normal aging increases risks of dysfunction and disease in androgen-responsive tissues, including brain. The use of testosterone therapy has the potential to increase the risks for developing prostate cancer and or accelerating its progression. To overcome this limitation, novel compounds termed "selective androgen receptor modulators" (SARMs) have been developed that lack significant androgen action in prostate but exert agonist effects in select androgen-responsive tissues. The efficacy of SARMs in brain is largely unknown. In this study, we investigate the SARM RAD140 in cultured rat neurons and male rat brain for its ability to provide neuroprotection, an important neural action of endogenous androgens that is relevant to neural health and resilience to neurodegenerative diseases. In cultured hippocampal neurons, RAD140 was as effective as testosterone in reducing cell death induced by apoptotic insults. Mechanistically, RAD140 neuroprotection was dependent upon MAPK signaling, as evidenced by elevation of ERK phosphorylation and inhibition of protection by the MAPK kinase inhibitor U0126. Importantly, RAD140 was also neuroprotective in vivo using the rat kainate lesion model. In experiments with gonadectomized, adult male rats, RAD140 was shown to exhibit peripheral tissue-specific androgen action that largely spared prostate, neural efficacy as demonstrated by activation of androgenic gene regulation effects, and neuroprotection of hippocampal neurons against cell death caused by systemic administration of the excitotoxin kainate. These novel findings demonstrate initial preclinical efficacy of a SARM in neuroprotective actions relevant to Alzheimer's disease and related neurodegenerative diseases.


Subject(s)
Acetanilides/pharmacology , Kainic Acid/pharmacology , Neurons/metabolism , Animals , Apoptosis , Cell Survival , Cells, Cultured , Female , Hippocampus/metabolism , Hormone Antagonists/pharmacology , Male , Neurodegenerative Diseases/metabolism , Neurons/drug effects , Neuroprotective Agents/pharmacology , Nitriles , Oxadiazoles , Rats , Rats, Sprague-Dawley , Risk , Signal Transduction
2.
Horm Behav ; 63(2): 301-7, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22554955

ABSTRACT

Age-related loss of sex steroid hormones is a established risk factor for the development of Alzheimer's disease (AD) in women and men. While the relationships between the sex steroid hormones and AD are not fully understood, findings from both human and experimental paradigms indicate that depletion of estrogens in women and androgens in men increases vulnerability of the aging brain to AD pathogenesis. We review evidence of a wide range of beneficial neural actions of sex steroid hormones that may contribute to their hypothesized protective roles against AD. Both estrogens and androgens exert general neuroprotective actions relevant to a several neurodegenerative conditions, some in a sex-specific manner, including protection from neuron death and promotion of select aspects of neural plasticity. In addition, estrogens and androgens regulate key processes implicated in AD pathogenesis, in particular the accumulation of ß-amyloid protein. We discuss evidence of hormone-specific mechanisms related to the regulation of the production and clearance of ß-amyloid as critical protective pathways. Continued elucidation of these pathways promises to yield effective hormone-based strategies to delay development of AD.


Subject(s)
Alzheimer Disease/metabolism , Gonadal Steroid Hormones/physiology , Alzheimer Disease/blood , Andropause/drug effects , Andropause/physiology , Animals , Estrogen Replacement Therapy/methods , Estrogens/pharmacology , Estrogens/therapeutic use , Female , Gonadal Steroid Hormones/blood , Humans , Male , Menopause/blood , Menopause/drug effects , Menopause/physiology , Risk Factors , Sex Factors
3.
Acta Pharmacol Sin ; 32(7): 861-72, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21685929

ABSTRACT

Ischemic insults on neurons trigger excessive, pathological glutamate release that causes Ca²âº overload resulting in neuronal cell death (excitotoxicity). The Ca²âº/calmodulin (CaM)-dependent protein kinase II (CaMKII) is a major mediator of physiological excitatory glutamate signals underlying neuronal plasticity and learning. Glutamate stimuli trigger autophosphorylation of CaMKII at T286, a process that makes the kinase "autonomous" (partially active independent from Ca²âº stimulation) and that is required for forms of synaptic plasticity. Recent studies suggested autonomous CaMKII activity also as potential drug target for post-insult neuroprotection, both after glutamate insults in neuronal cultures and after focal cerebral ischemia in vivo. However, CaMKII and other members of the CaM kinase family have been implicated in regulation of both neuronal death and survival. Here, we discuss past findings and possible mechanisms of CaM kinase functions in excitotoxicity and cerebral ischemia, with a focus on CaMKII and its regulation.


Subject(s)
Brain Ischemia/enzymology , Brain/enzymology , Calcium-Calmodulin-Dependent Protein Kinase Type 2/metabolism , Amino Acid Sequence , Animals , Brain/cytology , Brain/drug effects , Brain Ischemia/drug therapy , Brain Ischemia/metabolism , Calcium-Calmodulin-Dependent Protein Kinase Type 2/antagonists & inhibitors , Calcium-Calmodulin-Dependent Protein Kinase Type 2/chemistry , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Glutamic Acid/metabolism , Humans , Models, Molecular , Molecular Sequence Data , Neuroprotective Agents/therapeutic use , Protein Kinase Inhibitors/therapeutic use
4.
J Biol Chem ; 285(27): 20675-82, 2010 Jul 02.
Article in English | MEDLINE | ID: mdl-20424167

ABSTRACT

Ca(2+)/calmodulin (CaM)-dependent protein kinase II (CaMKII) is a major mediator of physiological glutamate signaling involved in higher brain functions. Here, we show CaMKII involvement in pathological glutamate signaling relevant in stroke. The novel inhibitor tatCN21 was neuroprotective even when added hours after glutamate insults. By contrast, the "traditional" inhibitor KN93 attenuated excitotoxicity only when present during the insult. Both inhibitors efficiently blocked Ca(2+)/CaM-stimulated CaMKII activity, CaMKII interaction with NR2B and aggregation of CaMKII holoenzymes. However, only tatCN21 but not KN93 blocked the Ca(2+)-independent "autonomous" activity generated by Thr-286 autophosphorylation, the hallmark feature of CaMKII regulation. Mutational analysis further validated autonomous CaMKII activity as the drug target crucial for post-insult neuroprotection. Overexpression of CaMKII wild type but not the autonomy-deficient T286A mutant significantly increased glutamate-induced neuronal death. Maybe most importantly, tatCN21 also significantly reduced infarct size in a mouse stroke model (middle cerebral arterial occlusion) when injected (1 mg/kg intravenously) 1 h after onset of arterial occlusion. Together, these data demonstrate that inhibition of autonomous CaMKII activity provides a promising therapeutic avenue for post-insult neuro-protection after stroke.


Subject(s)
Calcium-Calmodulin-Dependent Protein Kinase Type 2/metabolism , Neuroprotective Agents/pharmacology , Amino Acid Sequence , Animals , Animals, Newborn , Benzylamines/pharmacology , Calcium/pharmacology , Calcium-Calmodulin-Dependent Protein Kinase Type 2/antagonists & inhibitors , Calcium-Calmodulin-Dependent Protein Kinase Type 2/genetics , Calmodulin/pharmacology , Cell Death , Cerebral Cortex/cytology , Cerebral Cortex/physiology , Gene Expression Regulation, Enzymologic , Gene Products, tat/chemistry , Gene Products, tat/pharmacology , Hippocampus/cytology , Hippocampus/physiology , Mice , Molecular Sequence Data , Neurons/cytology , Neurons/drug effects , Neurons/physiology , Peptide Fragments/pharmacology , Protein Kinase Inhibitors/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, N-Methyl-D-Aspartate/drug effects , Receptors, N-Methyl-D-Aspartate/physiology , Stroke/drug therapy , Sulfonamides/pharmacology
5.
FEBS Lett ; 583(22): 3577-81, 2009 Nov 19.
Article in English | MEDLINE | ID: mdl-19840793

ABSTRACT

CaMKII, a major mediator of synaptic plasticity, forms extra-synaptic clusters under ischemic conditions. This study further supports self-aggregation of CaMKII holoenzymes as the underlying mechanism. Aggregation in vitro was promoted by mimicking ischemic conditions: low pH (6.8 or less), Ca(2+) (and calmodulin), and low ATP and/or high ADP concentration. Mutational analysis showed that high ATP prevented aggregation by a mechanism involving T286 auto-phosphorylation, and indicated requirement for nucleotide binding but not auto-phosphorylation also for extra-synaptic clustering within neurons. These results clarify a previously apparent paradox in the nucleotide and phosphorylation requirement of aggregation, and support a mechanism that involves inter-holoenzyme T286-region/T-site interaction.


Subject(s)
Adenosine Diphosphate/pharmacology , Adenosine Triphosphate/pharmacology , Calcium-Calmodulin-Dependent Protein Kinase Type 2/metabolism , Animals , Blotting, Western , Calcium/metabolism , Calcium/pharmacology , Calcium-Calmodulin-Dependent Protein Kinase Type 2/chemistry , Calcium-Calmodulin-Dependent Protein Kinase Type 2/genetics , Calmodulin/metabolism , Cell Hypoxia , Cell Line , Cells, Cultured , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Humans , Hydrogen-Ion Concentration , Ischemia/physiopathology , Models, Molecular , Mutation , Neurons/cytology , Neurons/enzymology , Neurons/metabolism , Phosphorylation/drug effects , Protein Conformation/drug effects , Spodoptera
6.
Mol Biol Cell ; 18(12): 5024-33, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17942605

ABSTRACT

Ca(2+)/calmodulin (CaM)-dependent protein kinase II (CaMKII) is a major mediator of cellular Ca(2+) signaling. Several inhibitors are commonly used to study CaMKII function, but these inhibitors all lack specificity. CaM-KIIN is a natural, specific CaMKII inhibitor protein. CN21 (derived from CaM-KIIN amino acids 43-63) showed full specificity and potency of CaMKII inhibition. CNs completely blocked Ca(2+)-stimulated and autonomous substrate phosphorylation by CaMKII and autophosphorylation at T305. However, T286 autophosphorylation (the autophosphorylation generating autonomous activity) was only mildly affected. Two mechanisms can explain this unusual differential inhibitor effect. First, CNs inhibited activity by interacting with the CaMKII T-site (and thereby also interfered with NMDA-type glutamate receptor binding to the T-site). Because of this, the CaMKII region surrounding T286 competed with CNs for T-site interaction, whereas other substrates did not. Second, the intersubunit T286 autophosphorylation requires CaM binding both to the "kinase" and the "substrate" subunit. CNs dramatically decreased CaM dissociation, thus facilitating the ability of CaM to make T286 accessible for phosphorylation. Tat-fusion made CN21 cell penetrating, as demonstrated by a strong inhibition of filopodia motility in neurons and insulin secrection from isolated Langerhans' islets. These results reveal the inhibitory mechanism of CaM-KIIN and establish a powerful new tool for dissecting CaMKII function.


Subject(s)
Biological Products/pharmacology , Calcium-Calmodulin-Dependent Protein Kinase Type 2/antagonists & inhibitors , Calcium-Calmodulin-Dependent Protein Kinase Type 2/metabolism , Protein Kinase Inhibitors/pharmacology , Amino Acid Sequence , Animals , Biological Products/chemistry , Cell Line , Hippocampus/drug effects , Hippocampus/enzymology , Insulin/metabolism , Insulin Secretion , Islets of Langerhans/drug effects , Islets of Langerhans/metabolism , Male , Models, Molecular , Molecular Sequence Data , Peptides/metabolism , Phosphorylation , Protein Binding , Protein Kinase Inhibitors/chemistry , Protein Structure, Tertiary , Rats , Rats, Wistar , Spodoptera , Substrate Specificity
7.
Biophys J ; 86(4): 2251-60, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15041664

ABSTRACT

Elevated concentrations of intracellular calcium in erythrocytes increase membrane order and susceptibility to secretory phospholipase A2. We hypothesize that calcium aids the formation of domains of ordered lipids within erythrocyte membranes by interacting directly with the inner leaflet of the cell membrane. The interface of these domains with regions of more fluid lipids may create an environment with weakened neighbor-neighbor interactions that would facilitate phospholipid migration into the active site of bound secretory phospholipase A2. This hypothesis was investigated by determining the effects of seven other divalent ions on erythrocyte membrane properties. Changes in membrane order were assessed with steady-state fluorescence spectroscopy and two-photon microscopy with an environment-sensitive probe, laurdan. Each ion increased apparent membrane order in model membranes and in erythrocytes when introduced with an ionophore, suggesting that direct binding to the inner face of the membrane accounts for the effects of calcium on membrane fluidity. Furthermore, the degree to which ions affected membrane properties correlated with the ionic radius and electronegativity of the ions. Lastly, erythrocytes became more susceptible to enzyme hydrolysis in the presence of elevated intracellular levels of nickel and manganese, but not magnesium. These differences appeared related to the ability of the ions to induce a transition in erythrocyte shape.


Subject(s)
2-Naphthylamine/analogs & derivatives , Cations, Divalent/blood , Erythrocyte Membrane/metabolism , Lipids/blood , Membranes, Artificial , Phospholipases A/metabolism , 2-Naphthylamine/chemistry , Erythrocytes/metabolism , Humans , Laurates/chemistry , Phospholipases A2 , Spectrometry, Fluorescence
SELECTION OF CITATIONS
SEARCH DETAIL
...